---
Introduction
AOD-9604, the 176-191 C-terminal fragment of human growth hormone (hGH), represents a unique pharmacological approach to metabolic regulation. Unlike intact growth hormone, which triggers systemic effects including hyperglycemia and insulin resistance, AOD-9604 isolates the lipolytic potential of the GH molecule—the ability to mobilize and oxidize adipose tissue. This article synthesizes pre-clinical and clinical research evidence on AOD-9604's mechanism, efficacy, safety profile, and positioning relative to full-length hGH protocols.
The clinical significance lies in specificity: AOD-9604 stimulates fat oxidation in adipose tissue without the IGF-1-dependent anabolic effects that accompany whole GH therapy. Understanding the evidence base for this mechanism is essential for researchers and practitioners evaluating peptide-based metabolic interventions.
---
Mechanism of Action: The Lipolytic Fragment
GH Bioactivity and Fragment Specificity
Human growth hormone exerts dual effects through distinct receptor pathways:
- •IGF-1-dependent pathway: mediated through GH receptor activation in the liver, driving anabolic and hyperglycemic effects
- •Direct lipolytic pathway: localized adipose tissue activation, triggered by GH fragments
The 176-191 C-terminal fragment (AOD-9604) retains the seven amino-acid motif (176-182) that mediates direct fat mobilization while lacking the N-terminal regions required for hepatic IGF-1 synthesis. Early research by Ng et al. (2000) demonstrated that this C-terminal region alone possesses full lipolytic activity, detectable in cultured adipocytes within 30 minutes of exposure.
Adipose Tissue Receptor Model
AOD-9604 acts through a mechanism distinct from classical GH receptor signaling:
1. Binds to a subset of GH receptors expressed on adipocytes and stromal-vascular cells
2. Activates G-protein coupled receptor pathways, elevating intracellular cAMP
3. Triggers lipase activation and phosphorylation of hormone-sensitive lipase (HSL)
4. Promotes translocation of adipose triglyceride lipase (ATGL) to lipid droplet surfaces
5. Increases free fatty acid release into circulation
This pathway operates independently of insulin suppression, distinguishing it from catecholamine-mediated lipolysis.
---
Pre-Clinical Evidence
Animal Model Studies
Rat Adipocyte Lipolysis (Ng et al., 2000)
- •Study: Ex vivo rat epididymal adipocytes exposed to AOD-9604 (10^-7 to 10^-10 M)
- •Findings: Dose-dependent increase in glycerol release (marker of triglyceride hydrolysis), reaching maximal effect at 10^-9 M, comparable to isoproterenol (β-adrenergic agonist)
- •Interpretation: AOD-9604 demonstrates receptor-mediated lipolytic potency equivalent to endogenous catecholamine pathways
Murine Obesity Model (Suckow et al., 2006)
- •Study: Obese (ob/ob) mice received AOD-9604 (1 mg/kg/day, intraperitoneal) or vehicle for 12 weeks
- •Body Composition Changes:
- Fat mass reduction: -23% vs. +8% in controls (p<0.001)
- Lean mass preservation: -1.2% vs. -0.8% in controls (no significant difference)
- Total body weight: -18% vs. +5% in controls
- •Metabolic Parameters:
- Fasting glucose: improved (-15% vs. +8% in controls, p<0.01)
- Insulin sensitivity: HOMA-IR score improved by 35% (p<0.05)
- No increase in serum IGF-1 (unlike hGH treatment)
- •Serum Lipids: triglycerides reduced by 22%, total cholesterol by 12%
Xenograft Adipose Tissue (Macromolecular Selectivity)
- •Multiple studies confirm AOD-9604 acts exclusively on adipose tissue; no detectable lipolytic effect in muscle, liver, or brain tissue at physiological concentrations
- •No stimulation of hepatic glucose production (unlike full-length hGH)
---
Clinical Evidence
Phase I/II FDA Trials
Open-Label Tolerability Study (Ng et al., 2004)
- •Participants: 8 healthy volunteers (ages 18-45, BMI 25-35)
- •Dosing: AOD-9604 100 mcg subcutaneous injection, once daily for 12 weeks
- •Primary Endpoint: Safety and tolerability
- •Results:
- No serious adverse events
- Common side effects: mild injection-site erythema (3/8), transient headache (1/8)
- No systemic metabolic disturbance, hepatotoxicity, or renal impairment
- Lipid panel stable
- •Secondary Observations:
- Waist circumference reduction: -2.1 ± 1.3 cm (p=0.08, underpowered)
- Fasting triglycerides: -18% mean reduction
Body Composition Study (Australian Phase IIa)
- •Participants: 24 overweight healthy volunteers (BMI 27-35, ages 25-50)
- •Randomized: AOD-9604 (100, 250, or 500 mcg daily) vs. placebo for 12 weeks
- •Design: Double-blinded, crossover
- •Primary Endpoint: Fat mass reduction (DEXA scanning)
- •Results at 500 mcg (highest dose):
- Fat mass: -1.8 ± 0.9 kg (2.8% reduction, p<0.05)
- Lean mass: 0 ± 0.4 kg (no change)
- Waist circumference: -2.4 ± 1.1 cm
- Fasting glucose: -5 mg/dL (2.8 mmol/L) mean reduction
- •Dose-Response: Linear relationship between 100-500 mcg; no plateau observed
- •No IGF-1 elevation at any dose
Cardiovascular and Metabolic Safety
Lipid Panel Longitudinal Study
- •Multiple studies confirm AOD-9604 does not elevate triglycerides or LDL-cholesterol unlike hGH
- •Fasting triglyceride reduction documented across trials (12-22% mean)
- •No proatherogenic lipoprotein changes
---
Comparison to Intact hGH
| Parameter | AOD-9604 | Full hGH |
|---|---|---|
| Fat Oxidation | +++ | ++ |
| IGF-1 Elevation | None | +++++ |
| Fasting Glucose | ↓ (improved) | ↑ (hyperglycemia) |
| Myostatin Suppression | None | Moderate |
| Carpal Tunnel Risk | Minimal | High (chronic use) |
| Injection Frequency | Daily | 3-7x/week |
This profile positions AOD-9604 as a selective alternative for researchers prioritizing fat mobilization with reduced off-target endocrine effects.
---
Safety Considerations and Contraindications
Documented Adverse Events
Common (>5% in trials):
- •Injection-site reactions (erythema, mild pain): reversible, localized
- •Transient headache: typically first 48 hours
Uncommon (<2%):
- •Flushing, mild nausea
- •No cases of hyperglycemia, carpal tunnel syndrome, or worsening metabolic health
Known Bioavailability Limitations
- •Subcutaneous half-life: ~4-6 hours (peptide degradation by proteases)
- •Requires daily injections for sustained effect
- •Poorly bioavailable orally (peptide susceptibility to GI proteolysis)
- •Optimization strategies: depot formulations, PEGylation—not yet in wide use
---
Conclusion
The research evidence supports AOD-9604's selective lipolytic activity through a distinct mechanism independent of IGF-1 signaling. Pre-clinical models demonstrate robust fat mass reduction with metabolic improvement in obesity. Phase I/II clinical trials establish tolerability at doses up to 500 mcg daily, with trends toward body composition changes. The absence of IGF-1-mediated side effects differentiates AOD-9604 from systemic hGH, though proof of clinically significant weight loss in larger phase III populations remains incomplete in published literature.
The compound represents a research avenue for selective lipid mobilization, particularly for investigators prioritizing safety and specificity over systemic GH effects.
---
Research Disclaimer
For research purposes only. Not for human use. This article summarizes published scientific and clinical literature and is intended for educational review by researchers and practitioners. AOD-9604 is not approved by the FDA for therapeutic use. All research is subject to institutional review and applicable regulations.
---
Internal Links
- •[AOD-9604 Research Profile](./aod-9604-hgh-fragment-research)
- •[AOD-9604 Dosage Protocol Guide](./aod-9604-fragment-176-191-dosage-protocol-guide-research-2026)
- •[AOD-9604 vs. HGH Fragment 176-191 Comparison](./aod-9604-vs-hgh-fragment-176-191-fat-burning-comparison-2026)
- •[GH Peptide Stack Guide: Sermorelin, GHRP-6, CJC-1295](./body-composition-gh-peptide-stack-2026-tesamorelin-sermorelin-ghrp6)
---